Back to top
more

Compugen (CGEN)

(Real Time Quote from BATS)

$1.65 USD

1.65
134,670

+0.02 (1.23%)

Updated Aug 8, 2024 09:48 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Ginkgo (DNA) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On Ginkgo's (DNA) fourth-quarter earnings call, investor focus is likely to be on the sales performance of its two business units, Biosecurity and Cell Engineering.

Eton Pharma (ETON) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Eton Pharma's (ETON) revenues in the fourth quarter of 2023 are expected to have been driven by the sales of its marketed products.

Compugen (CGEN) is a Great Momentum Stock: Should You Buy?

by Zacks Equity Research

Does Compugen (CGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Biotech Stock Roundup: CGEN Up on GILD Deal, MRNA Gains on Study Data & More

by Zacks Equity Research

Compugen (CGEN) and Moderna (MRNA) are in the news on collaboration and study updates, respectively.

Gilead (GILD), Compugen Collaborate for Immunotherapy Program

by Zacks Equity Research

Gilead (GILD) enters into a license agreement with Compugen for its pre-clinical immunotherapy program.

Is Compugen (CGEN) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Compugen (CGEN) and Evogene (EVGN) have performed compared to their sector so far this year.

Karuna (KRTX) Submits NDA Filing to FDA for Schizophrenia Drug

by Zacks Equity Research

If approved, Karuna's (KRTX) KarXT will be the first new mechanism of action to treat schizophrenia in several decades. Data from three clinical studies support the FDA filing.

Is Aspira Women's Health (AWH) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Aspira (AWH) and Compugen (CGEN) have performed compared to their sector so far this year.

Has Compugen (CGEN) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Compugen (CGEN) and Corcept Therapeutics (CORT) have performed compared to their sector so far this year.

Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how ANI Pharmaceuticals (ANIP) and Compugen (CGEN) have performed compared to their sector so far this year.

Is Certara (CERT) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Certara, Inc. (CERT) and Compugen (CGEN) have performed compared to their sector so far this year.

Ensign Group (ENSG) Ups Credit Facility to $600M to Fuel Growth

by Zacks Equity Research

Ensign Group (ENSG) expands its credit facility by $250 million to continue with its series of acquisitions, renovation of projects, business requirements et al.

UnitedHealth (UNH) to Spend $5.4B on Home-Health Profile Boost

by Zacks Equity Research

UnitedHealth (UNH) intends to combine its Optum business with LHC Group to expand its reach in the healthcare-at-home market.

    UnitedHealth (UNH) Arm Optum Acquires Refresh Mental Health

    by Zacks Equity Research

    UnitedHealth (UNH) unit Optum's acquisition of Refresh Mental Health comes at a time when demand for behavioral health services is on the rise.

      Ensign Group (ENSG) Up 9.9% in 3 Months: More Room to Grow?

      by Zacks Equity Research

      Ensign Group (ENSG) expects annual revenues for 2022 in the band of $2.93-$2.98 billion, whose midpoint signals a 12.4% rise from the 2021 reported figure.

        Compugen (CGEN) Stock Up on Bristol Myers' $20M Investment

        by Zacks Equity Research

        Compugen (CGEN) announces an expansion of its collaboration agreement with Bristol Myers Squibb and a $20 million equity investment by the latter.

        Can Coronavirus Vaccine Efforts Aid BioNTech (BNTX) Q3 Earnings?

        by Zacks Equity Research

        On BioNTech's (BNTX) upcoming Q3 earnings call, investors' focus will be on the progress and advancement of its COVID-19 vaccine candidate, currently being developed in partnership with Pfizer.

        Insight Enterprises' (NSIT) Q3 Earnings Top Estimates, Up Y/Y

        by Zacks Equity Research

        Insight Enterprises' (NSIT) Q3 performance benefits from acquisition of PCM amid sluggish demand from Asia Pacific and EMEA.

        What Awaits AVEO Pharmaceuticals (AVEO) in Q3 Earnings?

        by Zacks Equity Research

        On AVEO Pharmaceuticals' (AVEO) third-quarter earnings call, investor focus will be on the updates related to its NDA that seeks an approval for tivozanib to treat RCC in the United States.

        What's in Store for ADMA Biologics' (ADMA) Q3 Earnings?

        by Zacks Equity Research

        On ADMA Biologics' (ADMA) third-quarter earnings call, investor focus will be on the sales performance of its newly approved immunoglobulin products, Asceniv and Bivigam.

        What's in Store for Selecta (SELB) This Earnings Season?

        by Zacks Equity Research

        In absence of any marketed product, investor focus will be on Selecta's (SELB) efforts to develop its lead pipeline candidate SEL-212 during the third-quarter conference call.

        Can Trikafta Drive Vertex's (VRTX) Revenues in Q3 Earnings?

        by Zacks Equity Research

        On Vertex's (VRTX) third-quarter earnings call, investor focus will be on the sales performance of its triple combo CF drug Trikafta and the probable impact of COVID-19 on the same.

        Is the Options Market Predicting a Spike in Compugen (CGEN) Stock?

        by Zacks Equity Research

        Investors need to pay close attention to Compugen (CGEN) stock based on the movements in the options market lately.

        How Compugen (CGEN) Stock Stands Out in a Strong Industry

        by Zacks Equity Research

        Compugen (CGEN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

        Top Ranked Momentum Stocks to Buy for May 8th

        by Zacks Equity Research

        Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, May 8th.